Antitumor reactivity of T cells transduced with CTE-engineered γ9δ2TCRs in vitro. Peripheral blood T cells were virally transduced with indicated γ9δ2TCRs and tested against indicated tumor cell lines and healthy control tissue. (A) Transductants were incubated with target cells (E:T, 1:1) in the presence of 10μM pamidronate. IFNγ production was measured after 24 hours by ELISA. Data represent the means ± SD. *P < .05; **P < .01; and ***P < .001 by 1-way ANOVA. (B) Transductants were incubated with indicated tumor targets loaded with ⁵¹Cr (E:T, 10:1). Percentage of specific lysis was determined by ⁵¹Cr-release measured in the supernatant after 5 hours. (C) CTE-engineered T cells were tested against primary AML blasts and healthy progenitor cells in an IFNγ ELISpot assay (E:T, 3:1) in the presence of 10μM pamidronate. Data represent the means ± SD. *P < .05; **P < .01; and ***P < .001 by 1-way ANOVA.